Members of our Luxembourg team acted for CapVest on a key milestone in a major continuation fund transaction for Curium Group, involving the onboarding of new long-term investors and the launch of a renewed investment platform. This marks the largest transaction in nuclear medicine globally.
We advised on all Luxembourg legal aspects of the continuation fund and the broader transaction. This included structuring and execution a complex multi-step reorganisation, establishing and funding new Luxembourg holding entities, managing rollover and reinvestment mechanics for existing investors and management, and aligning governance, contribution, subscription, and distribution processes across the new structure.
This transaction required close coordination between our Corporate and Investment Management / Funds teams, whose technical expertise, responsiveness and collaboration were instrumental in its successful completion.
CapVest is a leading private equity investor and Curium Group develops, manufactures and supplies world-class radiopharmaceutical products around the globe.